文献速递白血病

急性髓系白血病中无事件生存的临床价值

Clinical value of event-free survival in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该回顾性研究纳入400例一线治疗的急性髓系白血病患者,分析无事件生存(EFS)与医疗资源使用的关系。结果显示,EFS延长与医疗资源使用显著下降相关,且不依赖总生存(OS)。

要点

  • EFS延长与总体医疗资源使用下降相关(r=-0.45)。
  • 该相关性在获得完全缓解的患者中更强。
  • EFS改善可作为独立于OS的临床获益指标。

核心结论

  • 在新诊断急性髓系白血病患者中,EFS改善与所有医疗资源使用下降相关,且不依赖OS持续时间。

研究设计与样本

  • 回顾性研究,纳入400例在一线治疗试验中治疗且OS在2至36个月之间的急性髓系白血病患者,从诊断至死亡或至干细胞移植删失时收集医疗资源使用数据,采用相关与回归分析。

主要发现

  • 35%的患者为不良风险AML,48%接受强化化疗,28%接受去甲基化药物。
  • 删失于干细胞移植的中位EFS为9.7个月。
  • EFS延长与总体医疗资源使用(r=-0.45)、门诊就诊、急诊就诊、住院及会诊总和(r=-0.44)、侵入性操作、实验室及影像学检查总和(r=-0.51)以及血制品输注(r=-0.19)均呈显著负相关。
  • 这些相关性在获得完全缓解的患者中更强,且在年龄、治疗和疾病风险亚组中均成立。

关键数值与推荐

  • EFS与总体医疗资源使用的相关系数r=-0.45。
  • EFS与门诊就诊、急诊就诊、住院及会诊总和的相关系数r=-0.44。
  • EFS与侵入性操作、实验室及影像学检查总和的相关系数r=-0.51。
  • EFS与血制品输注的相关系数r=-0.19。

临床怎么用

  • EFS可作为评估AML治疗获益的补充终点,反映医疗资源负担的减轻。
  • 临床决策中可关注EFS延长以减少医疗资源使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The value of event-free survival (EFS) as an end point in acute myeloid leukemia (AML) trials has been questioned. We hypothesized that rather than a surrogate for overall survival (OS), improvement in EFS may decrease the use of health care. In this retrospective study, we identified 400 patients with AML who were treated on first-line therapy trials and had OS between 2 and 36 months. We captured health care use from diagnosis until death or until the patient was censored at stem cell transplantation (SCT). We used correlation and regression analysis to determine the relation between health care use and EFS. Among patients with newly diagnosed AML, 35% had adverse-risk AML, 48% received intensive chemotherapy, and 28% received hypomethylating agents. The median EFS censored at SCT was 9.7 months. Longer EFS led to a significant decline in health care use regardless of OS. This held true for all observations, including overall health care use (r = -0.45), sum of clinic visits, emergency room visits, hospitalizations, consultations (r = -0.44), sum of invasive procedures, laboratory and imaging studies (r = -0.51), and blood product transfusions (r = -0.19). These correlations were stronger for patients who achieved a complete remission and held true across age, treatment, and disease risk subgroups. In patients with newly diagnosed AML, improvement in EFS correlates with a decrease in all health care use irrespective of OS duration.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Maiti A, Kantarjian HM, Popat V, et al. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020. PMID: 32330243. doi:10.1182/bloodadvances.2019001150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。